Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
1 drugs in development
By Therapeutic Area
top 0
No TA breakdown available.
R&D Momentum
56/100
Pipeline Velocity
30/100
Trial Completion Rate
100/100
Pipeline Concentration
100/100
Pipeline Freshness
48/100
Activity
Last 14 days
Effects of a Chatbot-Based Intervention on Resting-State Functional Connectivity and Spontaneous Neural Activity in Individuals With Anhedonia
Effects of a Chatbot-Based Intervention on Valence-Dependent Belief Updating and Expectancy Bias for Life Events in Individuals With Anhedonia
Effects of a Chatbot-Based Intervention on Behavioral Responsiveness and Neural Anticipation of Social and Monetary Incentives in Individuals With Anhedonia
Effects of a Chatbot-Based Intervention on Subjective Arousal and Neural Reactivity to Emotional Video Stimuli in Individuals With Anhedonia
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)